Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 29;10(11):407. doi: 10.3390/cancers10110407

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

(a) Course of CETCs in a patient with invasive ductal carcinoma (pT1bpN2aM0). Initially, an increase in cell numbers under radiotherapy was observed (hatched in yellow). Cell numbers remained primarily constant under further Tamoxifen therapy (blue). Follow-up samples of the patient revealed macroscopic complete remission (CR). (b) Course of CETCs in a patient with invasive lobular carcinoma who was treated with neoadjuvant therapy (ypT1a(m)pN1aM0). Under combined therapy comprising of Goserelin (hatched in dark blue) and Tamoxifen (blue), an initial decrease in CETCs was observed, followed by a renewed increase during further combination therapy. Under monotherapy with Tamoxifen a continuous decrease in CETCs was observed followed by a renewed increase of CETCs after completion of endocrine therapy. At that time the patient was macroscopically still in complete remission. After additional 10 months recurrence was confirmed and after mastectomy was treated with Paclitaxel (purple).